FMP
Milestone Pharmaceuticals Inc.
MIST
NASDAQ
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
1.8 USD
0.085 (4.72%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Joseph G. Oliveto M.B.A.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
CIK
0001408443
ISIN
CA59935V1076
CUSIP
59935V107
Address
1111 Dr. Frederik-Philips Boul...
Phone
15143360444
Country
CA
Employee
47
IPO Date
May 9, 2019
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
MIST Financial Summary
CIK
0001408443
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
59935V107
ISIN
CA59935V1076
Country
CA
Price
1.8
Beta
1.73
Volume Avg.
331.54k
Market Cap
95.99M
Shares
-
52-Week
1.12-2.93
DCF
-0.9
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.25
P/B
-
Website
https://www.milestonepharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MIST News
It looks like there's no news available.
